Biopharma | May 05, 2026
Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025
The private funding rose 38% amid growing international collaborations and CDMO demand
The private funding rose 38% amid growing international collaborations and CDMO demand
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
The company reported net revenue of SEK 13.5 million for the full year 2025
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Subscribe To Our Newsletter & Stay Updated
